Strata Critical Medical, Inc.
NASDAQ:SRTAAirlines, Airports & Air Services
-$0.03 today
- Market cap
- $443.03M
- Beta
- 2.20
- P/E (TTM)
- 9.7
- EPS (TTM)
- $0.60
Volume 0.99M
Average 0.91M
SRTA Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Strata Critical Medical, Inc.NASDAQ: SRTA
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $54.75M rose 29.4% year over year, ahead of the +6.0% change in trailing-twelve-month cost of revenue. Sequentially, it fell 3.3% from the prior quarter. Over 3 fiscal years it compounded at +8.6% a year.
Context
- Cost of revenue amounted to 80.6% of revenue in FY2025, up 4.3 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +29.4% holds above the trailing-twelve-month pace of +6.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 158.82M USD
- Year-over-year change
- -16.3%
- 4-year CAGR
- +41.2%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 158.82M | -16.3% |
| FY2024 | 2024-12-31 | 189.77M | +3.7% |
| FY2023 | 2023-12-31 | 183.06M | +47.8% |
| FY2022 | 2022-12-31 | 123.85M | +209.6% |
| FY2021 | 2021-09-30 | 40.01M | — |
Cost of Revenue vs competitors
How SRTA compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +6.0% is the 5th highest of 10, against a peer median of +0.2%.
- Cost of revenue amounts to 79.5% of revenue for SRTA, versus a peer median of 72.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Apr 2026 | $1.39B USD | -6.4% | -5.7% | 89.9% | |
| LTM Mar 2026 | $967.49M USD | -3.7% | -7.0% | 72.8% | |
| LTM Mar 2026 | $792.89M USD | +13.5% | +1.0% | 93.8% | |
| LTM Mar 2026 | $771.43M USD | +6.3% | +2.3% | 87.7% | |
| LTM Mar 2026 | $336.81M USD | +7.9% | +7.2% | 87.7% | |
| LTM Feb 2026 | $271.99M USD | -1.9% | -3.3% | 69.3% | |
SRTAStrata Critical Medical, Inc. | LTM Mar 2026 | $202.09M USD | +6.0% | +8.6% | 79.5% |
| LTM Mar 2026 | $96.61M USD | -10.5% | -9.6% | 52.8% | |
| LTM Mar 2026 | $48.59M USD | +0.2% | -17.6% | 10.9% | |
| LTM Mar 2026 | $35.49M USD | +14.8% | +41.2% | 40.3% | |
| LTM Mar 2026 | £15.22M GBP | — | -10.7% | — | |
| Peer median (excluding SRTA) | — | +0.2% | -4.5% | 72.8% | |
Competitors are the stored peer set for SRTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Sep 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.53M | 146.12M | 225.18M | 248.69M | 197.14M |
| Cost of Revenue | 40.01M | 123.85M | 183.06M | 189.77M | 158.82M |
| Gross Profit | 10.52M | 22.28M | 42.12M | 58.92M | 38.33M |
| Gross Margin | 20.8% | 15.2% | 18.7% | 23.7% | 19.4% |
| Research & Development | 1.68M | 5.55M | 4.63M | 3.18M | 3.05M |
| Selling, General & Admin | 32.93M | 70.26M | 105.61M | 89.66M | 45.08M |
| Operating Expenses | 34.61M | 75.8M | 110.24M | 92.85M | 48.13M |
| Depreciation & Amortization | 596K | 5.73M | 7.11M | 5.96M | 6.9M |
| EBITDA | (43.1M) | (22.31M) | (50.43M) | (21.6M) | (13.17M) |
| EBITDA Margin | -85.3% | -15.3% | -22.4% | -8.7% | -6.7% |
| Operating Income | (24.09M) | (53.53M) | (68.12M) | (33.93M) | (9.81M) |
| Operating Margin | -47.7% | -36.6% | -30.3% | -13.6% | -5.0% |
| Interest Income | 460K | 3.43M | 8.44M | 7.21M | 4.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (19.6M) | 25.5M | 10.58M | 6.36M | (10.26M) |
| Income Before Tax | (43.7M) | (28.03M) | (57.54M) | (27.56M) | (20.07M) |
| Pre-Tax Margin | -86.5% | -19.2% | -25.6% | -11.1% | -10.2% |
| Income Tax Expense | (3.64M) | (772K) | (1.47M) | (255K) | 0 |
| Net Income | (40.05M) | (27.26M) | (56.08M) | (27.31M) | (15.65M) |
| Net Margin | -79.3% | -18.7% | -24.9% | -11.0% | -7.9% |
| EPS (Basic) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| EPS (Diluted) | (0.57) | (0.38) | (0.76) | (0.35) | (0.19) |
| Weighted Avg Shares | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
| Weighted Avg Shares (Diluted) | 70.1M | 71.24M | 73.52M | 77.5M | 82.45M |
Strata Critical Medical, Inc.
NASDAQ:SRTA
Intrinsic Alpha fair value
Locked
Current Price
$4.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.